DETERMINED

Natalie is Chief Executive Officer (CEO) of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas.

Prior to Third Harmonic Bio, Natalie served as President and CEO of Audentes, an Astellas company. She joined the company as Senior Vice President (SVP) and Chief Operating Officer (COO) in August 2015 and was subsequently promoted to President and COO in May 2018, and then to President and CEO in January 2020. Prior to joining Audentes, Natalie served as SVP, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.

Natalie holds an A.B. in human biology from Stanford University and an M.A. in molecular, cellular, and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow.

Edward is the Chief Medical Officer (CMO) of Third Harmonic Bio where he oversees the clinical development strategy for the company. Edward has extensive experience in clinical development, translational medicine, and clinical strategy, including broad experience in early- to late-stage and post-marketing products.

Edward joined Third Harmonic Bio from Locanabio, where he served as CMO. Prior to Locanabio, Edward was Site Lead and Division Head of Medical and Development for Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, he served as CMO and Senior Vice President of Audentes Therapeutics, where he led functions including clinical development and operations, medical affairs, regulatory, drug safety, and patient advocacy. Before Audentes, Edward served as CMO of Sangamo Therapeutics. Earlier in his career, he was a Medical Director at Genentech, Inc. (now a member of the Roche Group) where he led clinical development programs for XOLAIR® (omalizumab) for the treatment of chronic urticaria and allergic asthma.

Edward earned a M.D. from the University of California, San Francisco, completed his residency in Internal Medicine at the University of Michigan and his fellowship in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. degree in biology from Duke University.

XOLAIR® is a registered trademark of Novartis AG.

Bob is Chief Financial Officer (CFO) of Third Harmonic Bio. Previously, he served as CFO at Neoleukin Therapeutics, Inc., a publicly held biopharmaceutical company, where he oversaw finance, information technology and business operations. Prior to Neoleukin, Bob was a Vice President in the Investment Banking Division of Morgan Stanley & Co, where he advised companies on financing and strategic matters. In this role, he successfully executed more than $9 billion in financings and participated in the completion of more than $5 billion in M&A transactions. Bob also served as a Senior Finance Director at Davita, Inc., a leading provider of kidney dialysis services. He received his B.B.A. in accountancy and computer applications from the University of Notre Dame and his M.B.A. from the University of Virginia Darden School of Business.

Julie Person is the Chief Administrative Officer at Third Harmonic Bio. She brings more than 20 years of experience in building biopharma organizations that align people practices with strategy to drive successful outcomes for patients and teams. In her role, Julie oversees human resources, corporate communications, and facilities.

Julie joined Third Harmonic Bio from Neumora Therapeutics, where she served as Chief People Officer and oversaw human resources and internal communications. Prior to Neumora, she was Head of Human Resources at Audentes Therapeutics and Sangamo Therapeutics, Inc. Prior to Sangamo, Julie was the Global Head of Talent Management at Shire Plc, where she played a key role in the integrations of both Baxalta International Inc. to Shire, and Shire into Takeda Pharmaceutical Company Ltd. Prior to Shire, she spent 12 years at McKesson Corp. in various HR roles of increasing responsibility.

Julie received her undergraduate degree in communications from Saint Mary’s College of California and completed the University of Michigan Ross School of Business Executive Leadership Program.

Adrian is Chief Scientific Officer at Third Harmonic Bio. He joined Third Harmonic Bio with more than 25 years of scientific and biotech industry experience, with a focus on the discovery and clinical translation of transformative medications from target selection to registrational filing. Before joining Third Harmonic Bio, he served as Senior Vice President Biology and Translation at Morphic Therapeutic, where he built the translation function and shaped the discovery pipeline in fibrosis, immunology, and oncology. Earlier, Adrian spent 15 years at Gilead Sciences, where he held positions of increasing responsibility in research and development. He has directly contributed to regulatory filings including over a dozen IND and NDA filings across therapeutic areas. He has published over 100 peer-reviewed papers and is an inventor on over 30 US-granted patents. Adrian graduated with highest honors from the University of California, Santa Cruz, with a B.A. in molecular, cellular, and developmental biology and received his Ph.D. for his work in the pharmacology department at Yale University.

Steve is Senior Vice President, Development Operations at Third Harmonic Bio. He began his career in clinical research over 20 years ago and held leadership positions in clinical operations and clinical technology at both Pfizer and Infinity Pharmaceuticals before making the transition to biotech start-ups. Since 2012, he has worked as Head of Development Operations at several Atlas-seeded companies including Arteaus Therapeutics (migraine), Annovation BioPharma (sedation and general anesthesia), Quartet (pain), and Rodin Therapeutics (synaptopathies). His development experience spans Phase 1 first-in-human studies through Phase 3b global registration studies and includes the design and implementation of technology to improve trial analytics and processes. Steve earned his bachelor’s degree in toxicology from Northeastern University.